Your browser doesn't support javascript.
loading
Mpox Vaccine Interest Survey Prioritization and Data Flow: Maricopa County, Arizona, July-August 2022.
Howard, Brandon J; Collins, Jennifer E; Staab, R Nicholas; Singh, Sonia; Lara, Erika; Kretschmer, Melissa; Rehder, Lori; Dellos, Anne; White, Jessica R; Dale, Ariella P.
Afiliação
  • Howard BJ; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • Collins JE; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • Staab RN; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • Singh S; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • Lara E; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • Kretschmer M; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • Rehder L; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • Dellos A; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • White JR; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
  • Dale AP; The authors are with the Maricopa County Department of Public Health, Phoenix, AZ.
Am J Public Health ; 113(5): 504-508, 2023 05.
Article em En | MEDLINE | ID: mdl-36893362
ABSTRACT
With increasing mpox cases in Maricopa County, Arizona, the county's health department launched a survey on July 11, 2022, to gather eligibility and contact data and provide clinic information to those interested in JYNNEOS as postexposure prophylaxis (PEP) or expanded postexposure prophylaxis(PEP++). Survey data were matched to case and vaccination data. Overall, 343 of the 513 respondents (66.9%) who reported close contact with an mpox case patient received PEP and 1712 of the 3379 respondents (50.7%) who were unsure of their contact status received PEP++. This outreach intervention connected potential close contacts unknown to MCDPH with PEP or PEP++. (Am J Public Health. 2023;113(5)504-508. https//doi.org/10.2105/AJPH.2023.307224).
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina Antivariólica / Vacinas / Mpox Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Am J Public Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Azerbaidjão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina Antivariólica / Vacinas / Mpox Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Am J Public Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Azerbaidjão